Myeloid Leukemia Clinical Trial
Official title:
Frequency and Risk Factors of Acute Myeloid Leukemia at Clinical Haemtology Unit of Assiut University Hospital
1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital 2. to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia
Acute myeloid leukaemia (AML) is a rare heterogeneous disease comprising a group of hematopoietic neoplasms originating from the excessive clonal proliferation of myeloid pre- cursor cells [1]. Diagnosis of AML is based on morphological diagnosis with proliferation of blast cells ≥ 20% of bone marrow cells, flow cytometric analysis and cytogenetic abnormalities, including the t(8;21)(q22;q22), t(15;17) (q22;q12) and inv (16)(p13.1;q22) which are associated with longer remission and survival, while alterations of chromosomes 5, 7, complex karyotype and 11q23 are associated with poor response to therapy and shorter overall survival [2] The etiological agent and pathogenesis of AML are not entirely clear, only few AML cases can be accurately classified through traditional cellular morphological classification [3]It is the most common acute leukaemia in adults. It accounts for 1.3% of new cancer patients in the United States, in 2018[ 4] Some factors are well documented to increase the risk of some types of leukemia such as benzene exposure and ionizing radiation [5] increased frequency of acute myeloid leukemia has been noticed at Haematology unit so the aim of the study to assess the the frequency of acute myeloid leukemia and to evaluate the risk factors for it . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Terminated |
NCT00543972 -
Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT00521664 -
A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups
|
Phase 3 | |
| Completed |
NCT05363488 -
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT00126893 -
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT03613727 -
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
|
Phase 2 | |
| Active, not recruiting |
NCT04714372 -
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06235801 -
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT02763475 -
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
|
Phase 2 | |
| Terminated |
NCT01643603 -
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00497991 -
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
|
Phase 1 | |
| Withdrawn |
NCT05309018 -
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
|
||
| Completed |
NCT04628338 -
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
| Completed |
NCT02719821 -
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
|
N/A | |
| Active, not recruiting |
NCT00111345 -
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
|
Phase 2/Phase 3 | |
| Completed |
NCT00114764 -
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
|
Phase 2 | |
| Recruiting |
NCT05871008 -
Integrated Actionable Aging Assessment for Cancer Patients Pilot
|
N/A | |
| Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 |